Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

Diabetologia. 2010 Jan;53(1):204-5. doi: 10.1007/s00125-009-1572-8. Epub 2009 Oct 27.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus / drug therapy*
  • Dose-Response Relationship, Drug
  • Ethics, Medical*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / adverse effects
  • Insulin / analogs & derivatives*
  • Insulin / therapeutic use
  • Insulin Glargine
  • Insulin, Long-Acting
  • Neoplasms / chemically induced*
  • Neoplasms / epidemiology
  • Risk Factors
  • Safety

Substances

  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin Glargine